| NCT06947928 | Placebo-Controlled Trial of IFx-Hu2.0 Followed By Pembrolizumab In Checkpoint Inhibitor Naïve Participants With Advanced Or Metastatic Merkel Cell Carcinoma | NOT_YET_RECRUITING | PHASE2, PHASE3 | 2025-06-30 | 2032-12-30 | 2027-03-31 |
| NCT06940440 | IFx-Hu2.0 As An Adjunctive Therapy To Pembrolizumab In Advanced Or Metastatic Merkel Cell Carcinoma (MCC) | NOT_YET_RECRUITING | PHASE1 | 2025-04-30 | 2028-05-31 | 2026-05-31 |
| NCT04925713 | IFx-Hu2.0 for the Treatment of Patients With Skin Cancer | COMPLETED | PHASE1 | 2021-06-10 | 2022-03-10 | 2021-10-07 |
| NCT04160065 | Immunotherapy With IFx-Hu2.0 Vaccine for Advanced Non-melanoma Skin Cancers | COMPLETED | PHASE1 | 2020-03-03 | 2024-08-13 | 2023-10-19 |
| NCT03655756 | pDNA Intralesional Cancer Vaccine for Cutaneous Melanoma | COMPLETED | EARLY_PHASE1 | 2018-11-05 | 2020-11-30 | 2020-07-10 |